首页 | 本学科首页   官方微博 | 高级检索  
     


Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Authors:Arlene Chan  Beverly Moy  Janine Mansi  Bent Ejlertsen  Frankie Ann Holmes  Stephen Chia  Hiroji Iwata  Michael Gnant  Sibylle Loibl  Carlos H. Barrios  Isil Somali  Snezhana Smichkoska  Noelia Martinez  Mirta Garcia Alonso  John S. Link  Ingrid A. Mayer  Søren Cold  Serafin Morales Murillo  Miguel Martin
Affiliation:1. Breast Clinical Trials Unit, Breast Cancer Research Centre-WA & Curtin University, Perth, Australia;2. Breast Oncology Program, Massachusetts General Hospital Cancer Center, Boston, MA;3. Oncology & Haematology Clinical Trials, Guy’s and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King’s College, London, United Kingdom;4. Department of Oncology, Rigshospitalet, Copenhagen, Denmark;5. Texas Oncology/US Oncology Research, Houston, TX;6. Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada;7. Clinical Oncology, Aichi Cancer Center, Chikusa-ku, Nagoya, Japan;8. Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;9. Center for Hematology and Oncology Bethanien, Frankfurt, Germany;10. Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil;11. Department of Oncology, Dokuz Eylul Universitesi Tip Fakultesi Hastanesi Tibbi Onkoloji Anabilim Dali Mithatpa?a, Balçova, Izmir, Turkey;12. University Clinic for Radiotherapy and Oncology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia;13. Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain;14. Oncología Médica, Hospital Universitario Nuestra Señora de la Candelaria Ctra. Del Rosario, Sta. Cruz De Tenerife, Canarias;15. Breastlink Medical Group, Inc, Santa Ana, CA;16. Division of Hematology/Oncology, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Nashville, TN;17. Onkologisk Afdeling R, Odense University Hospital, Odense, Denmark;18. Hospital Universitario Arnau Vilanova Servei d’Oncologia Mèdica i Hematologia, Lleida, Spain;19. Physician Medical Center, Northwest Medical Specialties PLLC, Tacoma, WA;20. Breast Oncology, Saitama Cancer Center, Kita-Adachi, Japan;21. Oncología, Hospital Universitario Virgen del Rocio, Seville, Spain;22. Crown Princess Mary Cancer Centre, Westmead Hospital and University of Sydney, Sydney, NSW, Australia;23. Virginia Cancer Specialists, Arlington, VA;24. Texas Oncology – Round Rock, Austin, TX;25. Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, CA;26. The Breast Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom;27. Puma Biotechnology Inc., Los Angeles, CA;28. Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain
Abstract:
Keywords:Adjuvant therapy  Disease-free survival  Distant disease-free survival  Neoadjuvant therapy  Overall survival
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号